RECRUITING

Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

People living with HIV (PLWH) are 28 times more likely to be diagnosed with Human Papillomavirus (HPV) - associated anal cancer than the general population. The HPV vaccine is an effective and safe approach to prevent and reduce the risk of HPV-related disease among PLWH. HPV vaccine programs tailored and implemented in the HIV population are lagging for this high-risk group. The CDC's 4 Pillars Transformation Program is a multi-level, evidence-based intervention that has been successfully used to increase HPV vaccination in the general population and is ready to be tested in the high-risk HIV population, particularly PLWH in the rural South. This program offers providers and clinic staff evidence-based strategies to increase HPV vaccination uptake via training and educational resources. This study proposes to tailor and refine the 4 Pillars Program and conduct this project in three HIV clinics in Georgia.

Official Title

Implementing an Evidence-Based, Multilevel Intervention to Promote HPV Vaccination Among HIV Positive Adults

Quick Facts

Study Start:2023-05-22
Study Completion:2027-06-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05065840

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 45 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. * Has contraindications to receiving the HPV vaccine i.e., history of an anaphylactic allergy to latex, an immediate hypersensitivity to yeast, current moderate or severe acute illness, and/or are currently pregnant)

Contacts and Locations

Study Contact

Jessica Wells, PhD, RN
CONTACT
404-727-0518
jholme3@emory.edu
Robert Knott
CONTACT
404-727-3159
rknott@emory.edu

Principal Investigator

Jessica Wells, PhD, RN
PRINCIPAL_INVESTIGATOR
Emory University

Study Locations (Sites)

Albany Rural Model Clinic
Albany, Georgia, 31705
United States
AID Atlanta
Atlanta, Georgia, 30309
United States
Faebris
Atlanta, Georgia, 30311
United States
AHF Lithonia
Lithonia, Georgia, 30058
United States

Collaborators and Investigators

Sponsor: Emory University

  • Jessica Wells, PhD, RN, PRINCIPAL_INVESTIGATOR, Emory University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-05-22
Study Completion Date2027-06-01

Study Record Updates

Study Start Date2023-05-22
Study Completion Date2027-06-01

Terms related to this study

Keywords Provided by Researchers

  • Human Immunodeficiency Virus
  • Vaccination

Additional Relevant MeSH Terms

  • Human Papilloma Virus
  • Human Papilloma Virus Vaccine